Comparison of clinical outcomes between ticagrelor and clopidogrel in acute coronary syndrome: a comprehensive meta-analysis

M Sun, W Cui, L Li - Frontiers in cardiovascular medicine, 2022 - frontiersin.org
Background Ticagrelor is currently recommended for patients with the acute coronary
syndrome (ACS). However, recent studies have yielded controversial results. Objective To …

[HTML][HTML] Does individualized guided selection of antiplatelet therapy improve outcomes after percutaneous coronary intervention? A systematic review and meta …

N Yamani, S Unzek, MH Mankani, T Almas… - Annals of Medicine and …, 2022 - Elsevier
Background The potential benefits of individualized guided selection of antiplatelet therapy
over standard antiplatelet therapy in improving outcomes in patients undergoing …

Ticagrelor or prasugrel in patients with acute coronary syndromes and diabetes mellitus

G Ndrepepa, A Kastrati, M Menichelli… - Cardiovascular …, 2020 - jacc.org
Objectives The aim of this study was to assess the efficacy and safety of ticagrelor versus
prasugrel in patients with diabetes mellitus (DM) presenting with acute coronary syndromes …

Ticagrelor is not superior to clopidogrel in patients with acute coronary syndromes undergoing PCI: a report from Swedish Coronary Angiography and Angioplasty …

S Völz, P Petursson, J Odenstedt, D Ioanes… - Journal of the …, 2020 - Am Heart Assoc
Background Ticagrelor reduces ischaemic end points in acute coronary syndromes.
However, outcomes of ticagrelor versus clopidogrel in real‐world patients with acute …

Comparative safety and effectiveness of ticagrelor versus clopidogrel in patients with acute coronary syndrome: an on-treatment analysis from a multicenter registry

M Almendro-Delia, E Blanco-Ponce… - Frontiers in …, 2022 - frontiersin.org
Background: The net clinical benefit of ticagrelor over clopidogrel in acute coronary
syndrome (ACS) has recently been questioned by observational studies which did not …

[HTML][HTML] Clinical Efficacy and Safety of Reduced-Dose Prasugrel After Percutaneous Coronary Intervention for Taiwanese Patients with Acute Coronary Syndromes

HH Chang, CF Hung, YJ Chen… - Journal of Clinical …, 2024 - pmc.ncbi.nlm.nih.gov
Background/Objectives: The efficacy and safety of reduced-dose prasugrel (loading
dose/maintenance dose: 20/3.75 mg) in preventing major adverse cardiovascular events …

Efficacy and safety of clopidogrel versus ticagrelor as part of dual antiplatelet therapy in acute coronary syndrome—a systematic review and meta-analysis

N Bergh, A Myredal, P Nivedahl… - Journal of …, 2022 - journals.lww.com
The efficacy and safety of clopidogrel compared with ticagrelor as part of dual antiplatelet
therapy in patients, and in older patients, with acute coronary syndrome is reviewed …

Discharge of Acute Coronary Syndrome Patients on Sub-Optimal Dual Anti-Platelet Therapy: A Single Center Experience

JB Booker, AJ Nihart, MJ Campen… - … Drugs and Therapy, 2024 - Springer
Purpose To identify and quantify the reasons why acute coronary syndrome (ACS) patients
undergoing stenting at the University of New Mexico Hospital (UNMH) were prescribed sub …

Risk of bradyarrhythmia related to ticagrelor: A systematic review and meta-analysis

I Pujade, J Perino, C Mathieu, M Arnaud… - Pharmacological …, 2020 - Elsevier
Context Ticagrelor was related to bradycardia in DISPERSE-II trial. This risk has been
integrated into the European risk-management plan, and its use is warned in at-risk patients …

替格瑞洛对轻型急性脑卒中和TIA 患者血小板功能的影响.

宫垒, 孙海英, 蒋显锋, 宫平… - Tianjin Medical …, 2022 - search.ebscohost.com
目的探讨Sonoclot 法检测替格瑞洛对轻型急性缺血性脑卒中和短暂性脑缺血发作(TIA)
患者血小板功能的影响. 方法选取81 例轻型急性缺血性脑卒中和TIA 患者 …